Loomis Enhances Its Pharmaceutical Logistics with Kipfer-Logistik Acquisition

Loomis Boosts Pharma Operations Through New Acquisition

In a strategic move to expand its pharmaceutical logistics segment, Loomis AB has announced its intent to fully acquire Swiss-based Kipfer-Logistik GmbH. This acquisition, which Loomis International Corporate AG is facilitating, signifies a significant step towards enhancing the company’s offerings in temperature-controlled logistics for the pharmaceutical and healthcare sectors.

Kipfer-Logistik specializes in temperature-sensitive transport and storage, presenting an opportunity for Loomis to scale up its existing pharmaceutical logistics operations, which have been gradually established in Switzerland since 2024 under the Loomis Pharma brand. The merger is expected to leverage Kipfer-Logistik's established systems and reputation, allowing Loomis to provide a more comprehensive service range to its clientele.

Financial Overview

In its latest fiscal year, Kipfer-Logistik reported revenues of around CHF 9 million, equivalent to SEK 108 million, with a workforce comprising 28 employees dedicated to offering specialized logistics services. The integration of Kipfer-Logistik into Loomis's operations is projected to bolster the company’s earnings and enhance its operational profits by the end of 2025, contributing positively to the earnings per share (EPS) and overall EBITA numbers.

Strategic Implications

Aritz Larrea, the President and CEO of Loomis, expressed his enthusiasm about the acquisition, stating, "This acquisition accelerates the growth of Loomis Pharma by integrating a well-established Swiss logistics company specializing in high-security and temperature-controlled road freight transport. Together, we will provide our customers with an even more comprehensive range of services, thereby strengthening our market position."

This statement encapsulates Loomis's ambition to not only enhance its market presence but also to solidify its commitment to providing secure and efficient logistics solutions in the pharmaceutical sector. The acquisition is projected to be finalized on September 1, 2025, contingent upon certain regulatory conditions, marking a pivotal transition in Loomis's business trajectory.

Conclusion

As Loomis prepares for the closing of this acquisition, it sets the stage for a new era of growth focused on high-security and temperature-sensitive logistics. This strategic move highlights the company’s dedication to meeting the needs of the pharmaceutical industry effectively and setting a benchmark for service excellence in the logistics sector. This acquisition not only enhances Loomis's operational capacity but also reinforces its vision of establishing a robust presence in the European market, particularly within the pharmaceutical logistics domain.

For further updates, Loomis has encouraged stakeholders to visit their company website, ensuring transparency and open communication during this significant transition period. With Kipfer-Logistik on board, Loomis is geared for accelerated growth and enhanced service delivery in the sector.